BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30171198)

  • 1. Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42.
    Stevers M; Rabban JT; Garg K; Van Ziffle J; Onodera C; Grenert JP; Yeh I; Bastian BC; Zaloudek C; Solomon DA
    Mod Pathol; 2019 Jan; 32(1):88-99. PubMed ID: 30171198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
    Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
    Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of diffuse malignant peritoneal mesothelioma.
    Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
    Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation.
    Goode B; Joseph NM; Stevers M; Van Ziffle J; Onodera C; Talevich E; Grenert JP; Yeh I; Bastian BC; Phillips JJ; Garg K; Rabban JT; Zaloudek C; Solomon DA
    Mod Pathol; 2018 Apr; 31(4):660-673. PubMed ID: 29148537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma.
    Itami H; Fujii T; Nakai T; Takeda M; Kishi Y; Taniguchi F; Terada C; Okada F; Nitta Y; Matsuoka M; Sasaki S; Sugimoto S; Uchiyama T; Morita K; Kasai T; Kawaguchi R; Ohbayashi C
    Hum Pathol; 2021 May; 111():59-66. PubMed ID: 33667423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of localized pleural mesothelioma.
    Hung YP; Dong F; Dubuc AM; Dal Cin P; Bueno R; Chirieac LR
    Mod Pathol; 2020 Feb; 33(2):271-280. PubMed ID: 31371807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma.
    Shrestha R; Nabavi N; Volik S; Anderson S; Haegert A; McConeghy B; Sar F; Brahmbhatt S; Bell R; Le Bihan S; Wang Y; Collins C; Churg A
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.
    Xing D; Banet N; Sharma R; Vang R; Ronnett BM; Illei PB
    Hum Pathol; 2018 Feb; 72():160-166. PubMed ID: 29241740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid papillary mesothelial tumor.
    Churg A; Le Stang N; Dacic S; Pissaloux D; Begueret H; Dartigues P; Giusiano-Courcambeck S; Sequeiros R; Pairon JC; Tirode F; Galateau-Sallé F
    Mod Pathol; 2022 Jan; 35(1):69-76. PubMed ID: 34480081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L1CAM expression in cystic mesothelial lesions: a comparison with adenomatoid tumours, well-differentiated papillary mesothelial tumours and malignant mesotheliomas.
    Karpathiou G; Casteillo F; Dridi M; Papoudou-Bai A; Dumollard JM; Peoc'h M
    Histopathology; 2021 Aug; 79(2):272-274. PubMed ID: 33847416
    [No Abstract]   [Full Text] [Related]  

  • 11. Inactivation of
    Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
    Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma.
    Lee HE; Molina JR; Sukov WR; Roden AC; Yi ES
    Hum Pathol; 2018 Sep; 79():168-176. PubMed ID: 29763720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
    Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
    JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years.
    Vitlarov N; Burtscher E; Pfeiffenberger E; Wahl A; Hodja V; Jasarevic Z; Kashofer K; Offner FA
    Virchows Arch; 2023 Dec; 483(6):873-878. PubMed ID: 37428268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
    Hung YP; Chirieac LR
    Arch Pathol Lab Med; 2024 May; 148(5):e77-e89. PubMed ID: 38190277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A diagnostic approach to paratesticular lesions with tubulopapillary architecture: a series of 16 serous borderline tumors/low-grade serous carcinoma and 14 well-differentiated papillary mesothelial tumors and mesothelioma.
    Zafar R; Schrader LJ; Cheville JC; Schoolmeester JK; Roden AC; Aubry MC; Yi ES; Raghunathan A; Herrera-Hernandez L; Thompson RH; Boorjian SA; Leibovich BC; Keeney GL; Jimenez RE; Gupta S
    Hum Pathol; 2022 Oct; 128():31-47. PubMed ID: 35809685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological and immunohistochemical characteristics and
    Fujishima F; Konosu-Fukaya S; Nabeshima K; McNamara KM; Sakamoto K; Sakurada J; Sasano H; Nakamura Y
    Indian J Pathol Microbiol; 2021; 64(2):277-281. PubMed ID: 33851620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
    Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
    J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesotheliomas and Benign Mesothelial Tumors: Update on Pathologic and Imaging Findings.
    Bonde A; Singh R; Prasad SR; Kamireddy D; Aggarwal A; Ramani N; Saboo S; Shanbhogue K; Dasyam AK; Katabathina VS
    Radiographics; 2023 Mar; 43(3):e220128. PubMed ID: 36757881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
    Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.